BD vs IPO? Navigating Strategic Crossroads for China's MedTech and Biopharma at the 2025 Changping Healthcare Finance & Investment Forum
Amid the profound restructuring of the global landscape and the accelerating wave of technological revolution, China’s healthcare industry is undergoing a critical transition from scale expansion to high-quality development. In 2025, both the external environment and internal logic of the industry have undergone significant changes, with a profound transformation brewing. In the face of global supply chain adjustments, continuous technological breakthroughs, and capital market restructuring,A series of critical questions urgently need to be answered: How can capital precisely identify and efficiently empower core projects with breakthrough technologies and broad market prospects amidst the wave of technological iteration? How can diverse financial instruments be integrated to build a full-lifecycle financial support system covering R&D, clinical trials, production, and commercialization? Furthermore, how should enterprises formulate financing and internationalization development strategies that not only adapt to the complex geopolitical environment but also align with domestic policy orientations? These issues are not only crucial for the survival and development of individual enterprises but also represent the core propositions for facilitating qualitative industrial transformation and achieving a dual leap forward in both the healthcare and financial industries.
To systematically explore how financial capital has become the core engine driving technological breakthroughs, accelerating the commercialization of achievements, and expanding into global markets, this event is hosted by the People’s Government of Changping District, Beijing, and Beijing State-owned Capital Operation and Management Co., Ltd., and co-organized by the Administrative Committee of Future Science City (Life Science Park Administrative Committee), the Administrative Committee of Changping Park of Zhongguancun Science Park, the Development and Reform Commission of Changping District, Beijing, Beijing Changping Science Park Development Group Co., Ltd., Beijing Changke Jin Investment Co., Ltd., and Chongqing Arterial Orange Technology Co., Ltd. (VCBeat).2025 Changping Medical and Health Finance Investment Innovation Forum (CHIF)is set to officially launch on July 7, 2025. This forum focuses on“Innovation-Led Navigation, Industrial-Financial Leap”Centered on this theme, we will conduct in-depth discussions on cutting-edge topics such as global pharmaceutical investment and financing trends, innovative drug R&D, integration of emerging technologies, and international expansion. We invite authoritative experts, investment elites, and senior executives from pharmaceutical and medical device companies to analyze industry pain points from diverse perspectives, share response strategies, and uncover potential opportunities.
Focus on Practical Experience and Solutions。The forum takes an in-depth look at the core challenges in the convergence of the healthcare industry and financial investment: How can we break through homogeneous involution and identify technological anchor points for differentiated innovation and global competitiveness? How can government, industry, academia, research institutions, and investors build a collaborative ecosystem for the translation of synthetic biology achievements? How should companies at different development stages choose the optimal path for global expansion based on their pipeline advantages and financial strength? Review experts, corporate executives, leading investment bankers, and key capital decision-makers will provide case-based analyses to offer practical and actionable solutions.
Bringing together prominent guests and industry expertise.This forum will invite government leaders from both municipal and district levels, policy and regulatory experts, scientists, entrepreneurs, and investors to engage in exchanges, focusing on cutting-edge hotspots, discussing core issues, and delivering solutions. By establishing a platform for in-depth dialogue among industry, finance, government, and research sectors, the forum aims to build a bridge for attendees to communicate directly with industry authorities and gain a deep understanding of the pulse of industrial development.
Promote industrial integration and cooperative exchanges.The forum’s agenda focused on two key areas: the integration of technology and industry, and the construction of a full-chain ecosystem. It attracted attendees from diverse fields, including frontier technologies, pharmaceuticals and healthcare, financial investment, platforms, and distribution channels, thereby fostering cross-sector communication and collaboration across multiple industries. This initiative aims to unlock richer cooperation opportunities and facilitate the development of an industrial ecosystem characterized by collaborative innovation and mutual benefit.
Event Name: 2025 Changping Pharmaceutical and Health Financial Investment Innovation Forum (CHIF)
Event Theme: Innovation-Led, Industrial Leapfrog
Event Time: Monday, July 7, 13:30-17:40
Event Venue: Conference Room 18A, 1st Floor, Building D, Beijing Changping Petroleum Technology Exchange Center
Event Organization：
Organizer
People's Government of Changping District, Beijing Municipality
Beijing State-owned Capital Operation and Management Co., Ltd.
Organizer
Future Science City Management Committee (Life Park Management Committee)
Administrative Committee of Changping Park, Zhongguancun Science Park
Beijing Changping District Development and Reform Commission
Beijing Changping Science and Technology Park Development Group Co., Ltd.
Beijing Changkejin Investment Co., Ltd.
Chongqing Arterial Orange Technology Co., Ltd. (VCBeat)
13:30-13:40
▷ Conference Opening
Chapter 1: Industry as the Foundation
13:40-13:50
▷ Opening Remarks
13:50-14:10
▷ Bridges and Frontiers of Molecular Medicine (Tentative)
Academician Guest
14:10-14:30
▷ Industry as the Foundation: The DeepSeek Moment for China’s Innovative Drugs
Review and Approval Experts
14:30-14:50
▷ Breaking Down Technical Barriers—The Industrial Revolution of AI in Drug Discovery: How to Reshape the Value Chain of Pharmaceutical R&D
Chief Scientist
14:50-15:10
▷ Strategic Momentum—Restructuring of the Global Pharmaceutical Outsourcing Industry Chain and Strategic Choices for CXOs
Corporate Executive
15:10-15:30
▷ Striking at the Core—The Pilot-Scale Platform’s Revolution in Translating Synthetic Biology into Industry
Corporate Executive
Chapter 2: Finance as a Tool
15:30-15:50
▷ Biopharma Valuation Reshaping and Pricing Strategies Amid the Wave of IPO Break-Issues
Top-tier Securities Firms
15:50-16:00
▷ Ceremony Segment
Chapter 3: Synergy Between Industry and Finance
16:00-16:50
▷ Industry-Finance Synergy—From License-out and Business Development to NewCo: Global Financial Collaboration and Practices for High-Quality Chinese Healthcare Assets
Investment Elites, Pharmaceutical Executives, Legal Experts, etc.
16:50-17:40
▷ Synergy Between Industry and Finance—A New Ecosystem for the Development of High-Quality Medical Device Assets: BD or IPO?
Senior executives of medical device companies, investment elites, legal experts, etc.
The research and development (R&D) of innovative drugs has always been a core focus in pharmaceutical investment and financing, yet it remains a significant challenge. The drug development process is characterized by long cycles, substantial capital requirements, and high risks. On average, it takes 10–15 years from drug discovery to final regulatory approval and market launch, with investments reaching billions of dollars. Moreover, the R&D process faces multiple risks, including target validation failures, clinical trial setbacks, and safety concerns. However, successful development can yield substantial market returns. For instance, PD-1/PD-L1 inhibitors have rapidly become blockbuster products upon launch, with sales figures repeatedly hitting new highs. Against the backdrop of an aging global population and rising incidence of chronic diseases, the demand for innovative drugs continues to grow, attracting sustained capital inflow into this sector.How to strike a balance between high investment and high returns, and precisely screen innovative drug projects with potential,a key challenge facing investment institutions.
From a technological perspective, the integration of emerging technologies such as artificial intelligence (AI), gene editing, and cell therapy with the pharmaceutical industry has brought unprecedented opportunities to the sector. In drug development, AI can accelerate target discovery, optimize compound screening, and shorten the R&D cycle; gene editing technology holds promise for overcoming genetic diseases that are difficult to treat with conventional drugs; and cell therapy has demonstrated significant efficacy in areas such as oncology and autoimmune diseases. However, many accompanying challenges, including the standardization, quality control, and commercialization of these emerging technologies, remain to be addressed. Furthermore, the incomplete legal frameworks and regulatory policies related to emerging technologies have increased investment uncertainty.How to Accurately Assess the Commercial Value and Risks of Technologies in Their Early Stages of Development, is a question that investment institutions and pharmaceutical and medical device companies need to consider together.
Furthermore, the path to internationalization is fraught with challenges. In recent years, global expansion has become a focal point for pharmaceutical and medical device companies as well as investment institutions. According to research data from EY, by mid-January 2025, outbound transactions involving Chinese innovative drugs were highly active. Within just half a month, multiple biotechnology companies signed potential deals totaling nearly $8 billion, with several blockbuster deals reaching the $1 billion level. The GLP-1 receptor agonist and antibody-drug conjugate (ADC) sectors have remained particularly popular. At the J.P. Morgan Annual Healthcare Conference held this January, Chinese pharmaceutical companies made frequent appearances, with License-out and NewCo models sparking intense discussion among multinational corporations and becoming the center of attention for capital markets and industry observers. Driven by favorable new policies and positive market signals, the global expansion of Chinese pharmaceutical and medical device enterprises is entering a new stage of development. However, companies must still navigate numerous barriers, including regulatory and policy differences across countries and regions, high market entry thresholds, and cultural disparities.How to Formulate a Sound Internationalization Strategy, Break Through Multiple Barriers, and Successfully Embrace the Global MarketThese are key concerns for the pharmaceutical and healthcare industry during investment and financing processes.
At a critical juncture in the global transformation of the pharmaceutical and healthcare industry, the 2025 Changping Pharmaceutical and Healthcare Financial Investment Innovation Forum will establish a high-level, in-depth platform for exchange and collaboration. Through in-depth analysis of the industrial landscape, discussion of pressing challenges, and the presentation of replicable solutions, the forum will provide attendees with profound industry insights and valuable cooperation opportunities, injecting new momentum into the innovative development of the pharmaceutical and healthcare sector and financial investment.